Galena Biopharma, Inc. (GALE: Quote) announced a clinical development collaboration with Genentech/Roche and Henry Jackson Foundation for the Advancement of Military Medicine to develop NeuVax in combination with Herceptin in adjuvant breast cancer patients currently not eligible for Herceptin therapy.
As per the terms of the collaboration, Genentech and Galena will sponsor a randomized, blinded multicenter Phase 2 clinical study in adjuvant breast cancer in around 300 patients, scheduled to be initiated in the first half of 2012. Clinical studies presented by Galena Biopharma at the American Society of Clinical Oncology meeting in June 2011 demonstrated promising results of NeuVax in combination with Herceptin in preventing breast cancer recurrences.
Click here to receive FREE breaking news email alerts for Galena Biopharma, Inc. and others in your portfolio
by RTT Staff Writer
For comments and feedback: email@example.com